The -c(=x)- Is Part Of A -c(=x)x- Group, Wherein The X's Are The Same Or Diverse Chalcogens Patents (Class 546/263)
  • Patent number: 9416121
    Abstract: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: August 16, 2016
    Assignees: The Broad Institute, Inc., Massachusetts General Hospital
    Inventors: Deborah Hung, Sarah Stanley, Tomohiko Kawate, Noriakie Iwase, Motohisa Shimizu
  • Patent number: 8952151
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: February 10, 2015
    Assignee: Quanticel Pharmaceuticals, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Publication number: 20150018321
    Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
    Type: Application
    Filed: September 25, 2014
    Publication date: January 15, 2015
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Maurizio DELCANALE, Elisabetta ARMANI, Gabriele AMARI
  • Publication number: 20140315893
    Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder medi
    Type: Application
    Filed: November 22, 2012
    Publication date: October 23, 2014
    Inventors: Ferenc Fülöp, László Vígh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
  • Publication number: 20140274703
    Abstract: 4-amino-6-(pyridyl and 2-substitutedphenyl)-picolinic acids and their derivatives; 6-amino-2-(pyridyl and 2-substitutedphenyl)-pyrimidine-4-carboxylates and their derivatives; and methods of using the same as herbicides.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Dow AgroSciences LLC
    Inventors: Joseph D. ECKELBARGER, Jeffrey B. EPP, Lindsey G. FISCHER, Natalie C. GIAMPIETRO, Jeremy KISTER, Jeffrey PETKUS, Joshua ROTH, Norbert M. SATCHIVI, Paul R. SCHMITZER, Thomas L. SIDDALL, Carla N. YERKES
  • Publication number: 20140228408
    Abstract: The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and respiratory diseases.
    Type: Application
    Filed: August 31, 2012
    Publication date: August 14, 2014
    Applicant: AMAKEM NV
    Inventors: Jo Alen, Sandro Boland, Arnaud Pierre, Jean Bourin, Olivier Defert, Dirk Leysen
  • Publication number: 20140213591
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 31, 2014
    Applicant: Quanticel Pharmaceuticals, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Zhe Nie, Jeffrey Alan Stafford, James Marvin Veal, Michael Brennan Wallace
  • Publication number: 20140135301
    Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
    Type: Application
    Filed: January 22, 2014
    Publication date: May 15, 2014
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Maurizio Delcanale, Elisabetta Armani, Gabriele Amari
  • Patent number: 8716472
    Abstract: A tri-podal compound according to formula (I) wherein, each Z is the same and is a substituted or unsubstituted N-heteroaromatic single-, multiple-, or fused-ring; and each A is the same, and can represent a direct bond between the cyclohexane ring and Z, or a carboxamide group (—C(O)—N(H)—). Use of the compounds in combinatorial libraries, methods of making the tripodal compounds, sensor devices for detecting carbohydrate targets, and methods of using the tripodal compounds to detect carbohydrate targets in a sample are also disclosed.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: May 6, 2014
    Assignee: University of Rochester
    Inventors: Benjamin L. Miller, Prakash B. Palde, Peter C. Gareiss
  • Publication number: 20140121367
    Abstract: The present invention relates to the synthesis and application of novel chiral/achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.
    Type: Application
    Filed: April 9, 2012
    Publication date: May 1, 2014
    Inventors: Sundeep Dugar, Dinesh Mahajan, Frank Peter Hollinger
  • Publication number: 20140080768
    Abstract: The invention generally relates to Pro-Drugs of dihydroorotate dehydrogenase (DHODH) inhibitors and methods of use thereof. In certain embodiments, the invention provides a DHODH inhibitor compound including a cleavable functional group that increases bioavailability as compared to a form of the DHODH inhibitor without the functional group, rendering the former more suitable for therapeutic use.
    Type: Application
    Filed: September 19, 2012
    Publication date: March 20, 2014
    Inventors: Alan Palmer, Michael J. Hudson, Richard Todd, Patrick Camilleri
  • Publication number: 20130336903
    Abstract: A personal care composition is disclosed comprising a pH tuneable gellant. The pH tuneable gellant has a formula of: wherein R1 and R2 are aminofunctional end-groups; L1 is a backbone moiety having molecular weight from 14 to 500 g/mol; and at least one of L1, R1 or R2 comprises a pH-sensitive group; wherein R5 is an aminofunctional moiety; L2 is a backbone moiety having molecular weight from 14 to 500 g/mol; and at least one of L2 or R5 comprises a pH-sensitive group; and mixtures of [I] and [II]. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion or may comprise one or more actives or agents.
    Type: Application
    Filed: June 13, 2012
    Publication date: December 19, 2013
    Inventors: SUSANA FERNANDEZ PRIETO, JOHAN SMETS, BEATRIU ESCUDER GIL, JUAN FELIPE MIRAVET CELADES, VICENT JOSEP NEBOT CARDA, PAUL ROBERT TANNER
  • Patent number: 8603945
    Abstract: This disclosure relates to methods and compositions for modulating disease resistance in plants and transgenic plants.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: December 10, 2013
    Assignee: The Regents of the University of California
    Inventors: Colleen Marie Knoth, Thomas Eulgem, Thomas Girke
  • Patent number: 8530461
    Abstract: Azetidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: September 10, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bernd Nosse, Martin Fleck, Niklas Heine, Gerald Juergen Roth
  • Publication number: 20130209483
    Abstract: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.
    Type: Application
    Filed: November 30, 2012
    Publication date: August 15, 2013
    Applicant: SUTTER WEST BAY HOSPITALS
    Inventor: SUTTER WEST BAY HOSPITALS
  • Publication number: 20130157996
    Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.
    Type: Application
    Filed: June 21, 2012
    Publication date: June 20, 2013
    Applicant: Amgen Inc.
    Inventors: Kaustav Biswas, James Brown, Jian J. Chen, Vijay Keshav Gore, Scott Harried, Daniel B. Horne, Matthew R. Kaller, Qingyian Liu, Vu Van Ma, Holger Monenschein, Thomas T. Nguyen, David J. St. Jean, JR., Chester Chenguang Yuan, Wenge Zhong
  • Patent number: 8455654
    Abstract: A nanoscale pigment particle composition includes an organic benzimidazolone pigment, and a sterically bulky stabilizer compound, wherein the benzimidazolone pigment associates non-covalently with the sterically bulky stabilizer compound that is a substituted pyridine derivative; and the presence of the associated stabilizer limits the extent of particle growth and aggregation, to afford nanoscale pigment particles.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: June 4, 2013
    Assignees: Xerox Corporation, National Research Council of Canada
    Inventors: Rina Carlini, Darren Andrew Makeiff
  • Publication number: 20130137648
    Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
    Type: Application
    Filed: January 23, 2013
    Publication date: May 30, 2013
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventor: Chiesi Farmaceutici S.p.A.
  • Publication number: 20130079313
    Abstract: The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.
    Type: Application
    Filed: September 26, 2012
    Publication date: March 28, 2013
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventor: Chiesi Farmaceutici S.p.A.
  • Patent number: 8362256
    Abstract: The present invention relates to the salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridine carboxamide, especially hydrochloride and mesylate thereof, and the use of said salts in the preparation of an antineoplastic medicament.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: January 29, 2013
    Assignee: Jiangsu Hengrui Medicine Co. Ltd.
    Inventors: Kaihong Yuan, Piaoyang Sun, Yunshu Zhou, Yongjiang Chen
  • Patent number: 8338701
    Abstract: A photoelectric conversion device using a semiconductor fine material such as a semiconductor fine particle sensitized with a dye carried thereon, characterized in that the dye is a methine type dye having a specific partial structure, for example, a methine type dye having a specific carboxyl-substituted hetero ring on one side of a methine group and an aromatic residue substituted with a dialkylamino group or an organic metal complex residue on the other side of the methine group, or a methine type dye having a carboxyl-substituted aromatic ring on one side of a methine group and a heteroaromatic ring having a dialkylamino group or an organic metal complex residue on the other side of the methine group; and a solar cell using the photoelectric conversion element. The photoelectric conversion element exhibits a conversion efficiency comparable or superior to that of a conventionally known photoelectric conversion element sensitized with a methine type dye.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: December 25, 2012
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Masaaki Ikeda, Koichiro Shigaki, Teruhisa Inoue
  • Patent number: 8293898
    Abstract: There is described novel organo-platinum luminophores comprising a complex of formula I: The luminophores have application as the emissive component in organic light emitting diodes.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: October 23, 2012
    Assignee: University of York
    Inventors: Duncan W. Bruce, Valery Kozhevnikov
  • Publication number: 20120165528
    Abstract: The present invention relates to chiral binaphthyl compounds having good solubility and high helical twisting power. The chiral binaphthyl compounds as dopants in the liquid crystal compositions can help enhance the display quality of the liquid crystal panels.
    Type: Application
    Filed: April 27, 2011
    Publication date: June 28, 2012
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jian-Wen Lin, Chun-Ming Wu, Shih-Hsien Liu, Kung-Lung Cheng
  • Publication number: 20120157681
    Abstract: There is described novel organo-platinum luminophores comprising a complex of formula I: The luminophores have application as the emissive component in organic light emitting diodes.
    Type: Application
    Filed: December 16, 2011
    Publication date: June 21, 2012
    Applicant: UNIVERSITY OF YORK
    Inventors: Duncan W. Bruce, Valery Kozhevnikov
  • Publication number: 20120157314
    Abstract: The present invention relates to novel, herbicidally active picolinic acid derivatives of the formula (I) and to processes for preparation thereof. The present invention further provides for the use thereof as a herbicide, especially as a herbicide for selective control of weed plants in useful plant crops, and as a plant growth regulator alone or in combination with safeners and/or in a mixture with other herbicides.
    Type: Application
    Filed: October 21, 2011
    Publication date: June 21, 2012
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Hartmut AHRENS, Marco BRÜNJES, Hansjörg DIETRICH, Elmar GATZWEILER, Isolde HÄUSER-HAHN, Stefan LEHR, Dirk SCHMUTZLER
  • Patent number: 8106193
    Abstract: There is described novel organo-platinum luminophores comprising a complex of formula (I). The luminophores have application as the emissive component in organic light emitting diodes.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: January 31, 2012
    Assignee: University of York
    Inventors: Duncan W. Bruce, Valery Kozhevnikov
  • Publication number: 20110313130
    Abstract: A bifunctional chelating agent of the formula (I): wherein the variables R1, R1?, Q1, Q2 and M are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a stable or radioactive metal; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate.
    Type: Application
    Filed: February 18, 2011
    Publication date: December 22, 2011
    Inventors: Mike ADAM, Eszter Boros, Cara L. Ferreira, Chris Orvig, Eric William Price
  • Publication number: 20110257199
    Abstract: Novel dicationic terphenyl compounds and their aza analogues. Methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues. Processes for synthesizing novel dicationic terphenyl compounds and their aza analogues.
    Type: Application
    Filed: June 17, 2011
    Publication date: October 20, 2011
    Inventors: Richard R. Tidwell, David W. Boykin, W. David Wilson, Reto Brun, Karl Werbovetz, Mohamed A. Ismail, Reem K. Arafa, Laixing Hu
  • Publication number: 20110251158
    Abstract: Described herein are methods for treating inflammatory disorders or for inhibiting the build-up of arterial plaque. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.
    Type: Application
    Filed: September 16, 2010
    Publication date: October 13, 2011
    Applicant: Luna Innovations Incorporated
    Inventors: Christopher L. KEPLEY, Robert P. LENK, Darren K. MACFARLAND, Zhiguo ZHOU
  • Publication number: 20110183957
    Abstract: Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    Type: Application
    Filed: August 4, 2009
    Publication date: July 28, 2011
    Inventors: John Wityak, Leticia M. Toledo-Sherman, Celia Dominguez, Stephen Martin Courtney, Christopher John Yarnold, Paula C. De Aguiar Pena, Andreas Scheel, Dirk Winkler
  • Publication number: 20110144075
    Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
    Type: Application
    Filed: February 22, 2011
    Publication date: June 16, 2011
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Maurizio Delcanale, Elisabetta Armani, Gabriele Amari
  • Publication number: 20110144070
    Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.
    Type: Application
    Filed: February 22, 2011
    Publication date: June 16, 2011
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Maurizio Delcanale, Elisabetta Armani, Gabriele Amari
  • Patent number: 7901559
    Abstract: It is intended to provide a method for easily detecting a phosphorylated peptide (protein) in a test sample by using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) which has been conventionally employed in analyzing a protein; a polyacrylamide gel for electrophoresis to be used in the method; a method of producing the gel; and a synthesizing intermediate in producing the gel. The polyacrylamide gel for electrophoresis to be used in the method of the invention is characterized in that at least a part of the structure thereof has a structure represented by the following formula (I); wherein M2+represents a transition metal ion; and X represents a linker group.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: March 8, 2011
    Assignee: Nard Institute, Ltd.
    Inventors: Tohru Koike, Akihiko Kawasaki, Tatsuhiro Kobashi
  • Publication number: 20100317851
    Abstract: There is described novel organo-platinum luminophores comprising a complex of formula (I). The luminophores have application as the emissive component in organic light emitting diodes.
    Type: Application
    Filed: September 29, 2008
    Publication date: December 16, 2010
    Applicant: UNIVERSITY OF YORK
    Inventors: Duncan W. Bruce, Valey Kozhevnikov
  • Patent number: 7851701
    Abstract: A photoelectric conversion device using a semiconductor fine material such as a semiconductor fine particle sensitized with a dye carried thereon, characterized in that the dye is a methine type dye having a specific partial structure, for example, a methine type dye having a specific carboxyl-substituted hetero ring on one side of a methine group and an aromatic residue substituted with a dialkylamino group or an organic metal complex residue on the other side of the methine group, or a methine type dye having a carboxyl-substituted aromatic ring on one side of a methine group and a heteroaromatic ring having a dialkylamino group or an organic metal complex residue on the other side of the methine group; and a solar cell using the photoelectric conversion element. The photoelectric conversion element exhibits a conversion efficiency comparable or superior to that of a conventionally known photoelectric conversion element sensitized with a methine type dye.
    Type: Grant
    Filed: July 5, 2002
    Date of Patent: December 14, 2010
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Masaaki Ikeda, Koichiro Shigaki, Teruhisa Inoue
  • Patent number: 7812251
    Abstract: A photosensitizing transition metal complex of the formula (Ia) MLY1, (Ib) MLX3 (Ic) MLY2X, (Id) MLY3X or (Ie) MLY4X in which M is a transition metal selected from ruthenium, osmium, iron, rhenium and technetium, preferably ruthenium or osmium. X is a co-ligand independently selected from NCS—, Cl—, Br—, I—, CN—, H2O; pyridine unsubstituted or substituted by at least one group selected from vinyl, primary, secondary or tertiary amine, OH and C1-30 alkyl, preferably NSC and CN—; L is a tridentate polypyridine ligand, carrying at least one carboxylic, phosphoric acid or a chelating group and one substituted or unsubstituted alkyl group having 1 to 50 carbon atoms, substituted or unsubstituted alkylamide group having 2 to 30 carbon atoms or substituted or unsubstituted aralkyl group having 7 to 50 carbon atoms.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: October 12, 2010
    Assignee: Sharp Kabushiki Kaisha
    Inventors: Ashraful Islam, Liyuan Han, Atsushi Fukui
  • Publication number: 20100227887
    Abstract: The present invention relates to pyridine-2-yl-carboxylic acid amides which act as metabotropic glutamate receptor antagonists. In particular, the present invention relates to pyridine-2-yl-carboxylic acid amides of formula I wherein R1, R2, R3, and R4 are as described in the specification.
    Type: Application
    Filed: February 24, 2010
    Publication date: September 9, 2010
    Inventors: Georg Jaeschke, Eric Vieira, Juergen Wichmann
  • Publication number: 20100041568
    Abstract: A tri-podal compound according to formula (I) wherein, each Z is the same and is a substituted or unsubstituted N-heteroaromatic single-, multiple-, or fused-ring; and each A is the same, and can represent a direct bond between the cyclohexane ring and Z, or a carboxamide group (—C(O)—N(H)—). Use of the compounds in combinatorial libraries, methods of making the tripodal compounds, sensor devices for detecting carbohydrate targets, and methods of using the tripodal compounds to detect carbohydrate targets in a sample are also disclosed.
    Type: Application
    Filed: October 16, 2007
    Publication date: February 18, 2010
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Benjamin L. Miller, Prakash B. Palde, Peter C. Gareiss
  • Patent number: 7579475
    Abstract: The present invention provides a novel salt of S-(?)-amlodipine, i.e., a nicotinic acid salt of S-(?)-amlodipine, a process for preparing the same, and a pharmaceutical composition comprising the same as an active ingredient.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: August 25, 2009
    Assignee: Hanlim Pharmaceutical Co., Ltd.
    Inventors: You Sup Chung, Mun Choun Ha
  • Publication number: 20090062267
    Abstract: The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1, and also that exhibit appropriate selectivity profile(s) against other integrins.
    Type: Application
    Filed: January 29, 2008
    Publication date: March 5, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Jean-Claude Arnould, Benedicte Delouvrie, Christine Marie Paul Lambert-Van Der Brempt
  • Patent number: 7291580
    Abstract: 4-Aminopicolinic acids having (1,1-difluoroalkyl) substituents in the 6-position and their amine and acid derivatives are potent herbicides demonstrating a broad spectrum of weed control.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: November 6, 2007
    Assignee: Dow AgroSciences LLC
    Inventors: Terry William Balko, Stephen Craig Fields, Nicholas Martin Irvine, Christian Thomas Lowe, Paul Richard Schmitzer
  • Patent number: 7232817
    Abstract: ?- and ?-amino acid hydroxyethylamino sulfonyl urea derivative compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: June 19, 2007
    Assignees: G.D. Searle & Co., Monsanto Company
    Inventors: Michael L. Vazquez, Richard A. Mueller, John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, Eric T. Sun
  • Patent number: 6916800
    Abstract: The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: July 12, 2005
    Assignee: Pfizer Inc
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Patent number: 6858598
    Abstract: A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: February 22, 2005
    Assignee: G. D. Searle & Co.
    Inventors: John P. McKearn, Gary Gordon, James J. Cunningham, Stephen T. Gately, Alane T. Koki, Jaime L. Masferrer
  • Patent number: 6833378
    Abstract: Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: December 21, 2004
    Assignee: Pfizer Inc
    Inventor: Yuhpyng L. Chen
  • Patent number: 6818200
    Abstract: A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: November 16, 2004
    Assignee: Isotechnika Inc.
    Inventors: Robert T. Foster, Richard Lewanczuk, Gilles Caille
  • Patent number: 6726894
    Abstract: The invention relates to new compounds with the general formula I for use as a tool to introduce macromolecules into cells. The invention further relates to compositions for introducing macromolecules into cells, comprising vesicles formed by at least one compound in a solvent. The macromolecule can be incorporated in the vesicles and/or bound to the vesicles or another aggregate of the new compounds.
    Type: Grant
    Filed: December 28, 1998
    Date of Patent: April 27, 2004
    Assignee: Synvolux IP B.V.
    Inventors: Jan Bernard Frederik Nicolaas Engberts, Anno Wagenaar, Dirk Hoekstra, Irene Van Der Woude, Marcel Herman Jozef Ruiters
  • Patent number: 6699892
    Abstract: The present invention discloses a novel and improved pharmaceutical salt, nicotinate, of amlodipine having the following formula: The present invention also discloses methods for preparing and using the same.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: March 2, 2004
    Assignee: Yung Shin Pharmaceutical Industrial Co., Ltd.
    Inventors: Fang Yu Lee, Tsang-Miao Huang, Chao-Ho Chung
  • Patent number: 6624178
    Abstract: The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, of the general formula I, or pharmaceutically acceptable salts thereof, wherein, R1, R2, R3, X and m are as defined in the specification.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: September 23, 2003
    Assignee: Torrent Pharmaceuticals Ltd.
    Inventor: Alangudi Sankaranarayanan
  • Patent number: 6608060
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: August 19, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy W. Bemis, Francesco Gerald Salituro, John Patrick Duffy, John E. Cochran, Edmund Martin Harrington, Mark A. Murko, Keith P. Wilson, Michael Su, Vincent P. Galullo